Scarica l'app Stockscreener
12.68
2.46%
-0.32
Precedente Chiudi:
$13.00
Aprire:
$13.21
Volume 24 ore:
154.93K
Relative Volume:
1.40
Capitalizzazione di mercato:
$463.79M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-20.25%
1M Prestazione:
-4.45%
6M Prestazione:
-43.57%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$12.50
$13.24
Intervallo di 1 settimana:
$12.50
$16.04
Portata 52W:
$12.09
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
1325 BOYLSTON STREET, BOSTON
Confronta RAPP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
12.68 | 463.79M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-02 | Iniziato | Jefferies | Buy |
| 2024-07-02 | Iniziato | Stifel | Buy |
| 2024-07-02 | Iniziato | TD Cowen | Buy |
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5%Here's What Happened - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
How To Trade (RAPP) - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.6%What's Next? - MarketBeat
Jennison Associates LLC Acquires Shares of 62,287 Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Short Interest Down 15.3% in January - MarketBeat
JPMorgan Chase & Co. Purchases Shares of 4,033 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 4.6%Here's What Happened - MarketBeat
J&J-backed Rapport Therapeutics files for $100M IPO - MSN
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
(RAPP) Proactive Strategies - Stock Traders Daily
Rapport Therapeutics (RAPP) Projected to Post Quarterly Earnings on Thursday - Defense World
‘A really rational IPO environment’: What does it takes for a biotech to go public now? - Fierce Biotech
Barclays PLC Increases Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month LowWhat's Next? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownWhat's Next? - MarketBeat
Rapport Therapeutics Announces Positive Results from PET and MAD-2 Trials for RAP-219On January 9, 2025, Rapport Therapeutics, Inc. (NASDAQ: RAPP) disclosed the outcomes from its positron emission tomography (PET) trial and the second multiple as - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%What's Next? - MarketBeat
(RAPP) Technical Data - Stock Traders Daily
Rapport Therapeutics announces new Phase 1 data for RAP-219 - Yahoo Finance
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
CORRECTION -- Rapport Therapeutics Announces New Phase 1 - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
Rapport Therapeutics Announces New Phase 1 Data, Further - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - GlobeNewswire Inc.
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's ... - The Bakersfield Californian
Rapport Therapeutics (NASDAQ:RAPP) Sets New 52-Week LowHere's What Happened - MarketBeat
Geode Capital Management LLC Makes New $4.13 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Geode Capital Management LLC Purchases New Shares in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Has $264,000 Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
State Street Corp Invests $1.19 Million in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
58,046 Shares in Rapport Therapeutics (NASDAQ:RAPP) Purchased by State Street Corp - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4%Here's Why - MarketBeat
Learn to Evaluate (RAPP) using the Charts - Stock Traders Daily
TARPγ8 negative allosteric modulators as new approach for epilepsy - BioWorld Online
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 - Business Wire
Shareholder Alert: Ademi LLP investigates whether Nordstrom, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
When (RAPP) Moves Investors should Listen - Stock Traders Daily
1,684 Shares in Rapport Therapeutics (NASDAQ:RAPP) Bought by BNP Paribas Financial Markets - Defense World
LTRPA, LTRPB Investors Have the Opportunity to Join Investigation of Liberty TripAdvisor Holdings, Inc. with the Schall Law Firm - Business Wire
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.6%Should You Sell? - MarketBeat
The Manitowoc Company reaches agreement to settle U.S. EPA matter regarding its emissions certification and compliance process - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7%Should You Buy? - MarketBeat
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Non sono disponibili dati finanziari per Rapport Therapeutics Inc (RAPP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Rapport Therapeutics Inc Azioni (RAPP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HEALY JAMES | Director |
Jun 10 '24 |
Buy |
17.00 |
558,824 |
9,500,008 |
1,863,327 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):